Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies

PURPOSE: To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. METHODS: We established 12 PDX from BRAF inhibitor progressed melanoma patients. Following expansion, PDX were analyzed using targeted sequencing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L., Xu, Xiaowei, Karakousis, Giorgos, Mills, Gordon B., Lu, Yiling, Ahmed, Tamer A., Poulikakos, Poulikos I., Caponigro, Giordiano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M., Weeraratna, Ashani T., Herlyn, Meenhard
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818716/
https://ncbi.nlm.nih.gov/pubmed/26673799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1762
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge